Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Similarity of GB222 and Bevacizumab in Healthy Volunteers
NCT04175158Phase 1Unknown
- Sponsor
- Genor Biopharma
- Start
- Apr 2017
- Primary completion
- Aug 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GB222 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Genor Biopharma. Primary endpoint: Area Under the Curve from time zero to last quantifiable concentration up to 84 days. Status: unknown.
02
Drugs
GB222
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04175158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04175158.